Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TH-302 plus doxorubicin versus doxorubicin in advanced soft tissue sarcoma
2011-003145-17Phase 3Completed
- Sponsor
- Threshold Pharmaceuticals
- Start
- Dec 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in soft tissue sarcoma (STS) comparing TH-302 + doxorubicin with doxorubicin alone (2 arms). Primary endpoint: Overall survival. Started Dec 2011; status: completed.
02
Drugs
evofosfamidedoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2011-003145-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003145-17.